To better coordinate and promote all graduate education at Marshall University Joan C. Edwards School of Medicine (JCESOM), we recently reorganized the Office of Research and Graduate Education. The office is located in Suite 301 in the Robert C. Byrd Biotechnology Science Center (BBSC). Along with the PhD, the MD/PhD, the Research MS and Medical Sciences MS in Biomedical Sciences, the new MS in Clinical and Translational Science degree is housed in this office. Second, a group consisting of current students, recent graduates, and faculty are redesigning the PhD curriculum, both modifying existing courses and adding new ones. These changes will better prepare our students to be more competitive in research that has become more translational and interdisciplinary.
As you can see, positive changes have taken place recently at the School of Medicine to significantly improve the education and training of our graduate students. Please feel free to stop by the Office of Research and Graduate Education to further explore these exciting new developments.
We will be a world leader in community academic clinical research supporting medical innovation and care in Appalachia. To realize this vision, we will strive to:
Below is a list of currently enrolling Clinical Trials at the Appalachian Clinical and Translational Science Institute (ACTSI). If you would like additional information about a specific trial, you can call the contact number provided and speak with a study coordinator.
Additional information about each trial can be obtained at ClinicalTrials.gov by clicking on the descriptions below
|Study ID||PI||Description||Contact Information|
|NCT02329327||Cornell||"A Study in Patients with Acute Major Bleeding to Evaluate the Ability of Andexanet Alfa to Revers the Anticoagulation Effect of Direct and Indirect Oral Anticoagulants (ANNEXA-4)"||Robin Ashford: 304-691-1082|
|NCT01442194||Ferguson||"Long-term, Prosepctive, Multi- national, parallel-cohort study Monitoring Safety in Patients with MS Newly Started with Fingolimod Once Daily or Treated with Another Approved Disease- Modifying Therapy" CLR1104||Linda Morgan: 304-691-1213|
|NCT02239120||Nolte||"Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS)"||Melissa Marcum: 304-691-8560
Rebecca Smith: 304-691-1834
|NCT02477618||Shah||"A Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of SAGE547 Injection in the Treatment of Subjects with Super Refrac-tory Status Epilepticus"||Robin Ashford: 304-691-1082
Doug Melton: 304-691-8618
|NCT01797185||Ferguson||"Open-label, safety study of SPARC1104 in Subjects with Spasticity due to MS"||Linda Morgan: 304-691-1213|
|NCT02373904||Cheung||"A Prospective, Multi-Center Study of the IlluminOSS Photodynamic Bone Sta-bilization System for the Treatment of Impending and Actual Pathological Fractures in the Humerus from Metastatic Bone Disease"||Linda Morgan: 304-691-1213|
|NCT03114657||Neitch||"A Phase III, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Study of Crenezumab in Patients with Prodromal to Mild Alzheimer's Disease"||Melissa Marcum: 304-691-8560|
|NCT02792218||Ferguson||"A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study Comparing the Efficacy and Safety of Ofatumumab versus Teriflunomide in Patients with Relapsing Multiple Sclerosis"||Linda Morgan: 304-691-1213
Doug Melton: 304-691-8618
|NCT02878330||Lambros||"A Phase 2B Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Safety and Efficacy of MEDI8897, a Mono-clonal Antibody with an Extended Half-Life Against Respiratory Synctial Virus, in Healthy Preterm Infants"||Robin Ashford: 304-691-1082|